MedTrace Logo

Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin)

NCT00955110 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2017-10-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the subjective and objective effects of Oxymorphone ER (Opana ER) versus Oxycodone CR (Oxycontin).

Conditions

  • Healthy

Interventions

DRUG

Oxymorphone ER

15mg or 30mg

DRUG

Oxycodone CR

30mg or 60mg

DRUG

Placebo

The placebo was a sugar pill.

DRUG

Hydromorphone

8 mg

Sponsors & Collaborators

  • Kendle Early Stage - Toronto

    collaborator OTHER

  • Endo Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00955110 on ClinicalTrials.gov